2024
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original Research
2020
Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).
Oh D, Ajani J, Bang Y, Chung H, Lacy J, Lee J, Macarulla T, Manji G, O'Reilly E, Allen S, Al-Sakaff N, Barak H, Patel J, Pintoffl J, Shemesh C, Zhang W, Zhang X, Chau I. Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). Journal Of Clinical Oncology 2020, 38: 712-712. DOI: 10.1200/jco.2020.38.4_suppl.712.Peer-Reviewed Original ResearchControl armPhase Ib/IIEarly efficacy signalsInjection-related reactionsImmune-mediated effectsSeparate randomized trialsHigh-affinity antagonistEvaluable ptsMetastatic PDACPrimary endpointRECIST 1.1II trialEfficacy signalsRandomized trialsSafety profileAtezoDuctal adenocarcinomaPK dataRandomized EvaluationCancerGr 3PDACTrialsWkEfficacy
2018
P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer
Johung K, Kann B, Lacy J, Stein S, Kortmansky J, Zaheer W, Cheng Y, Lam W, Liu S, Decker R, Hochster H, Higgins S. P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer. Annals Of Oncology 2018, 29: v90. DOI: 10.1093/annonc/mdy151.319.Peer-Reviewed Original ResearchO-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208
Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A, ECOG-ACRIN. O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. Annals Of Oncology 2018, 29: v110. DOI: 10.1093/annonc/mdy149.029.Peer-Reviewed Original ResearchRandomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.
Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A. Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. Journal Of Clinical Oncology 2018, 36: 3504-3504. DOI: 10.1200/jco.2018.36.15_suppl.3504.Peer-Reviewed Original ResearchEffect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.
Shitara K, Shah M, Di Bartolomeo M, Lonardi S, Al-Batran S, Van Cutsem E, Ilson D, Chau I, Alsina M, Lacy J, Takahari D, Sugimoto N, Bendell J, Wainberg Z, Tehfe M, Ferry D, Wei R, Walgren R, Das M, Fuchs C. Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. Journal Of Clinical Oncology 2018, 36: 4044-4044. DOI: 10.1200/jco.2018.36.15_suppl.4044.Peer-Reviewed Original Research
2017
622PD nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
Philip P, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Mozo J, Kim E, Dowden S, Zakari A, Borg C, Terrebonne E, Herrero F, Li J, Ong T, Nydam T, Hammel P. 622PD nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial. Annals Of Oncology 2017, 28: v212. DOI: 10.1093/annonc/mdx369.006.Peer-Reviewed Original Research730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)
Portales F, Philip P, Hammel P, Buscaglia M, Pazo-Cid R, Mozo J, Kim E, Dowden S, Zakari A, Borg C, Terrebonne E, Herrero F, Li J, Ong T, Nydam T, Lacy J. 730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). Annals Of Oncology 2017, 28: v248-v249. DOI: 10.1093/annonc/mdx369.114.Peer-Reviewed Original Research
2005
Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients
Burtness B, Gibson M, Lacy J, Rowen E, Thomas L, Sipples R, McGurk M, Murren J, Forastiere A. Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients. Journal Of Clinical Oncology 2005, 23: 4070-4070. DOI: 10.1200/jco.2005.23.16_suppl.4070.Peer-Reviewed Original Research